BlackRock, Inc.

Position in NBIX — Neurocrine Biosciences Inc

CIK 2012383 New York, NY

Position in NBIX

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$1,763,419,854

-$56,343,707 QoQ

Shares Held

13,385,607

+4.3% QoQ

Ownership

13.3%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2024

7 quarters on record

Voting authority Sole 93.57662301007343.ToString("F0")% Shared 0.ToString("F0")% None 6.4233769899265685.ToString("F0")%

Healthcare · as of Mar 31, 2026

BlackRock, Inc. holds $19,745,764,999 across 67 Drug Manufacturers - Specialty & Generic names. NBIX ranks #4 (8.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ZTS	Zoetis Inc.	35,584,312	$4,206,421,510
2	UTHR	UNITED THERAPEUTICS Corp	5,399,649	$3,201,883,855
3	TEVA	Teva Pharmaceutical Industries Ltd	65,136,464	$1,961,910,288
4	NBIX	Neurocrine Biosciences Inc This page	13,385,607	$1,763,419,854
5	VTRS	Viatris Inc	84,359,804	$1,139,700,941
6	ELAN	Elanco Animal Health Inc	47,622,630	$1,139,609,527
7	ALKS	Alkermes plc.	28,314,410	$1,001,197,527
8	LNTH	Lantheus Holdings, Inc.	8,183,193	$620,695,182

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,763,419,854	13,385,607	+4.3%	Shares	Sole	2026-05-13
2025-12-31	$1,819,763,561	12,830,597	+1.0%	Shares	Sole	2026-02-12
2025-09-30	$1,783,700,555	12,706,230	-1.9%	Shares	Sole	2025-11-12
2025-06-30	$1,628,284,399	12,954,765	-11.8%	Shares	Sole	2025-08-12
2025-03-31	$1,623,872,772	14,682,394	-0.7%	Shares	Sole	2025-05-02
2024-12-31	$2,017,841,547	14,782,722	+3.7%	Shares	Sole	2025-02-07
2024-09-30	$1,642,581,841	14,256,048	—	Shares	Sole	2024-11-13
No filing history on record for this holder in this stock.